DSP 0378
Alternative Names: DSP-0378Latest Information Update: 10 Oct 2025
At a glance
- Originator Sumitomo Pharma
- Class Antiepileptic drugs; Small molecules
- Mechanism of Action GABA A receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Brain disorders
- Preclinical Progressive myoclonic epilepsies
- Discontinued Dravet syndrome; Lennox-Gastaut syndrome
Most Recent Events
- 10 Oct 2025 Preclinical trials in Progressive-myoclonic-epilepsies in Japan (PO), prior to October 2025 (Sumitomo Pharma pipeline, October 2025)
- 09 Oct 2025 Phase-I clinical trials in Brain disorders in Japan (PO), prior to October 2025 (Sumitomo Pharma pipeline, October 2025)
- 08 Oct 2025 Discontinued - Phase-I for Dravet syndrome (In children, In infants, Treatment-resistant) in Japan (PO)